Hi [[ session.user.profile.firstName ]]

PMGroup

  • Date
  • Rating
  • Views
  • Strengthening market access deliverables by harnessing the patient journey Strengthening market access deliverables by harnessing the patient journey Dominic Tyer Recorded: Sep 14 2016 58 mins
    In today’s multi-stakeholder environment, pharma companies need to coordinate their stakeholder interactions between functions to ensure consistency of message and efficiency of cost.

    The patient journey can be at the centre of this drive by shaping an aligned communication on ‘value’.

    On 14 September Executive Insight, in association with PMGroup, will host a free webinar about how to leverage the patient journey to strengthen market access deliverables.

    It will investigate how to develop a common value story, what such a framework should look like and the role of cross-functional working when it comes to putting these ideas into practice.
  • The value of early asset development and commercialisation The value of early asset development and commercialisation Dominic Tyer Recorded: Jul 13 2016 56 mins
    Linking the clinical benefit of a product to a real-world benefit that markets care about, insurers will pay for and that will improve patients’ lives is critical for pipeline assets to succeed.

    On July 13 Cello Health, in association with PMGroup, will host a free webinar on the value of early asset development and commercialisation.

    It will follow the asset development journey, defining value from both a financial and clinical perspective, and look at the variables with which companies must contend in order to optimize a product’s prospects.
  • Developing medical education that advances patient outcomes Developing medical education that advances patient outcomes Dominic Tyer Recorded: Jun 30 2016 56 mins
    As pressure mounts on the pharmaceutical industry to demonstrate a tangible and positive impact on patients’ lives, understanding barriers to specific clinician behaviours is key to achieving measurable change in clinical practice and advancing patient outcomes.

    Medical education has the potential to affect a significant number of healthcare professionals’ (HCPs) clinical practice and so improve patients’ outcomes.

    Nonetheless, achieving these goals requires medical education to move beyond didactic message delivery - that only improves HCPs’ awareness - to using many multi-channel educational interventions to drive real behaviour change.

    In this webinar, Lucid will discuss why, as an industry, we should all be moving beyond our internal goals to think about how we can improve patient outcomes with all our programmes and share a process for creating measurable improvements.
  • Customer engagement design in pharma Customer engagement design in pharma Dominic Tyer Recorded: May 19 2016 56 mins
    In recent years pharma has slowly been realising the importance of customer experience and the fact that the commercial model that served it so well for the past 30 years might not be the right one for the future.

    But continued ‘evolution’ is no longer acceptable - a more revolutionary approach to customer engagement design that makes it easy for front line employees to engage andmakes it relevant and unique for the customer is needed before it is too late.

    On 19 May EY, in association with PMGroup, will host a free webinar on customer engagement design in pharma and time to move beyond the rhetoric, and I would like to invite you to register for it - either to watch it live on the day or for access to a recorded version.
  • Rare diseases: Regulatory and reimbursement submissions, the challenges Rare diseases: Regulatory and reimbursement submissions, the challenges Dominic Tyer Recorded: Mar 22 2016 74 mins
    Companies developing new rare disease treatments face several unique challenges when it comes to their regulatory and reimbursement submissions.

    One of the most pressing of these is the paucity of information on patient populations, disease progression and appropriate Clinical Outcome Assessments (COAs), which form an important part of assessing signs and symptoms of rare diseases and treatment response.
  • Meaningful Digital Initiatives Need Face Time Meaningful Digital Initiatives Need Face Time Dominic Tyer Recorded: Feb 10 2016 61 mins
    Recent global survey data confirms that pharmaceutical sales representatives are still doctors’ preferred source of pharmaceutical product information. Although doctors are increasingly using social media and other online channels in their professional capacity to search for and share information, face-to-face interactions still carry more trust and are more likely to influence prescribing. While pharma shouldn’t neglect digital channels as potentially valuable entry points for the promotion of assets, more meaningful and impactful marketing strategies will be those that pursue an optimal mix of face-to-face and digital initiatives.
  • Authentic Engagement in Healthcare Authentic Engagement in Healthcare DominicTyer Recorded: Nov 24 2015 61 mins
    What does ‘authenticity’ mean to the healthcare sector and how can companies best build authentic relationships with their stakeholders?

    For the past few years FleishmanHillard has researched the concept of authenticity and how the ‘authenticity gap’ between expectations and experience can impact the reputation of a company or sector.

    This work has produced nine drivers of reputation, which provide actionable insights for companies seeking to manage their reputation more effectively.

    On 24 November this PMGroup webinar, in association with FleishmanHillard, will draw on the latest UK research, with additional examples from Canada, Japan and Germany, and provide practical examples of how to remain authentic in an inauthentic world.

    I would like to invite you to register for this webinar - either to watch it live on the day or for access to a recorded version.
  • Can medical technology afford market access? Can medical technology afford market access? DominicTyer Recorded: Nov 18 2015 61 mins
    Medical technologies should be innovative, unique, and have technical feasibility and robust intellectual property. This does not, however, guarantee successful market access and reimbursement.

    Despite companies striving to improve patient care, many still struggle to gain market access - governed by three main factors: evidence requirements, the reimbursement landscape and defining clinical and economic value for medical devices.

    On 18 November Adelphi Values and two expert speakers, in association with PME, will explain these multiple challenges and discuss key considerations, potential challenges and solutions for gaining successful market access for often life-changing medical technologies.

    I would like to invite you to register for this webinar - either to watch it live on the day or for access to a recorded version.
  • Drivers for change - understanding payer value perceptions Drivers for change - understanding payer value perceptions Dominic Tyer - Editorial Director PMGroup Recorded: Sep 22 2015 61 mins
    In an ever-changing healthcare environment, the need to prove value for money remains a key focus for payers and reimbursement decision makers.

    New pricing regulations, broad-based healthcare reforms, tendering processes and an increased emphasis on value-based assessment are all changing the game for pricing and launch sequencing, while raising hurdles for market access.

    There’s no one-size-fits-all approach when it comes to defining value to meet the specific healthcare needs of national, regional and local payers, but it’s never been more critical to customising your value propositions in order to optimise reimbursement and patient access.

    So on 22 September this Adelphi Values webinar, in association with PMGroup, will focus on value evidence considerations by payer archetypes.
  • Sales reps in the digital age Sales reps in the digital age Dominic Tyer Recorded: Jul 9 2015 76 mins
    As the number of doctors willing to see pharmaceutical sales representatives in person declines how can digital tools help with access, reach and rep effectiveness?

    One of the factors blamed for the reduction in access was digital preferences – particularly among younger doctors.

    However, digital interactions – though clearly on the rise – can will never entirely supersede face-to-face contact, so how can the industry best get the digital/face-to-face mix right?

    This PMGroup webinar, in association with M3 Europe and Veeva Systems, will look at the place of sales reps in the digital age and how best to support them with digital tools and channels.

Embed in website or blog